Premium
Long‐term cohort study of chronic hepatitis C according to interferon efficacy
Author(s) -
Maruoka Daisuke,
Imazeki Fumio,
Arai Makoto,
Kanda Tatsuo,
Fujiwara Keiichi,
Yokosuka Osamu
Publication year - 2012
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.2011.06871.x
Subject(s) - medicine , proportional hazards model , cohort , retrospective cohort study , gastroenterology , hepatitis c , multivariate analysis , surgery
Background and Aim: We investigated the prognosis of patients with C‐viral chronic liver disease (C‐CLD) according to the efficacy of interferon (IFN) therapy in a long‐term retrospective cohort study. Methods: Of 721 patients with C‐CLD who underwent liver biopsy between January 1986 and December 2005, 577 were treated with IFN, and 221 of these patients achieved sustained virological response (SVR) with a follow‐up period of 9.9 ± 5.3 years. Results: The annual rate of HCC development was 2.71%/year, 2.31%/year, and 0.24%/year in untreated, non‐SVR, and SVR patients, respectively. Multivariate Cox proportional regression analysis showed that the risk of HCC development was significantly lower in SVR patients than in untreated or non‐SVR patients; moreover, this risk was similar in non‐SVR patients and untreated patients. The annual mortality rate in overall death was 3.19%/year, 1.98%/year, and 0.44%/year in untreated, non‐SVR, and SVR patients, respectively. Multivariate Cox proportional hazards regression analysis showed that the SVR status reduced the risk ratio for overall death to 0.173, whereas the non‐SVR status did not significantly reduce the risk ratio. Conclusions: The risk ratio of overall death and HCC development was significantly reduced in SVR patients, whereas no significant reduction was found in non‐SVR patients in a long‐term cohort study.